Akoya Biosciences Inc (NASDAQ: AKYA) on Tuesday, soared 4.52% from the previous trading day, before settling in for the closing price of $1.55. Within the past 52 weeks, AKYA’s price has moved between $1.55 and $6.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 23.82% annually for the last half of the decade. The company achieved an average annual earnings per share of 23.38%. With a float of $20.62 million, this company’s outstanding shares have now reached $49.52 million.
In an organization with 330 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 55.56%, operating margin of -52.17%, and the pretax margin is -66.62%.
Akoya Biosciences Inc (AKYA) Insider and Institutional Ownership
Observing investor behavior towards Medical Instruments & Supplies industry stocks is more important than anything else. The insider ownership of Akoya Biosciences Inc is 58.41%, while institutional ownership is 24.65%. The most recent insider transaction that took place on Jun 11 ’24, was worth 15,630. In this transaction President and CEO of this company sold 7,500 shares at a rate of $2.08, taking the stock ownership to the 224,733 shares. Before that another transaction happened on Jun 06 ’24, when Company’s President and CEO sold 7,500 for $2.01, making the entire transaction worth $15,064. This insider now owns 224,733 shares in total.
Akoya Biosciences Inc (AKYA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.38% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 31.86% during the next five years compared to -37.60% drop over the previous five years of trading.
Akoya Biosciences Inc (NASDAQ: AKYA) Trading Performance Indicators
Akoya Biosciences Inc (AKYA) is currently performing well based on its current performance indicators. A quick ratio of 1.85 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.62 in one year’s time.
Technical Analysis of Akoya Biosciences Inc (AKYA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.3 million. That was inferior than the volume of 0.87 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 13.37%. Additionally, its Average True Range was 0.16.
During the past 100 days, Akoya Biosciences Inc’s (AKYA) raw stochastic average was set at 9.55%, which indicates a significant decrease from 20.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.49% in the past 14 days, which was lower than the 85.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.4694, while its 200-day Moving Average is $2.4938. However, in the short run, Akoya Biosciences Inc’s stock first resistance to watch stands at $1.6967. Second resistance stands at $1.7733. The third major resistance level sits at $1.9067. If the price goes on to break the first support level at $1.4867, it is likely to go to the next support level at $1.3533. The third support level lies at $1.2767 if the price breaches the second support level.
Akoya Biosciences Inc (NASDAQ: AKYA) Key Stats
Market capitalization of the company is 80.31 million based on 49,573K outstanding shares. Right now, sales total 96,630 K and income totals -63,320 K. The company made 18,810 K in profit during its latest quarter, and -10,530 K in sales during its previous quarter.
